AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3925486 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.25 mg/kg oral)
Number of subjects: 10
Study 3925486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3925486 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone + Diazepam
Number of subjects: 10
Study 31246055 — intervention group
Group type: EXPERIMENTAL
Intervention: Accounts explaining why a company layoff was made
Number of subjects: 0
Study 31246055 — intervention group
Group type: EXPERIMENTAL
Intervention: Accounts describing how layoff recipients were treated respectfully
Number of subjects: 0
Study 29554966 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshops using cadaveric dislocation models
Number of subjects: 146
Study 29554966 — intervention group
Group type: COMPARATOR
Intervention: Instructional cards
Number of subjects: 146
Study 29554966 — intervention group
Group type: COMPARATOR
Intervention: Cadaveric instruction on the relocation of one-, two- or all three-joints
Number of subjects: 146
Study 29554966 — intervention group
Group type: COMPARATOR
Intervention: Skeleton model instruction
Number of subjects: 146
Study 26710675 — intervention group
Group type: EXPERIMENTAL
Intervention: Plus version of the intervention (targeting environmental-level factors)
Number of subjects: 100
Study 26710675 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic version of the intervention (targeting individual cognitions and self-regulation)
Number of subjects: 100
Study 26710675 — intervention group
Group type: COMPARATOR
Intervention: Control group (generic nutrition information)
Number of subjects: 100
Study 25134038 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-step facilitative intervention
Number of subjects: 234
Study 25134038 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline variables (122 total)
Number of subjects: 234
Study 21999668 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) to the wrist extensors, pulsed current, 100 Hz, pulse duration of 0.1 msec, resting duration of 9 seconds, for 15 minutes, combined with stretching.
Number of subjects: 0
Study 21999668 — intervention group
Group type: COMPARATOR
Intervention: Stretching of the wrist extensor muscles alone.
Number of subjects: 0
Study 20454667 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based intervention for non-gay identified MSM
Number of subjects: 329
Study 20454667 — intervention group
Group type: COMPARATOR
Intervention: Text-based intervention for non-gay identified MSM
Number of subjects: 329
Study 20454667 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based intervention for gay-identified MSM
Number of subjects: 329
Study 20454667 — intervention group
Group type: COMPARATOR
Intervention: Text-based intervention for gay-identified MSM
Number of subjects: 329
Study 18559301 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian/hops fluid extract (2 ml diluted in 50 ml water, administered 15 minutes before EEG recording)
Number of subjects: 42
Study 18559301 — intervention group
Group type: COMPARATOR
Intervention: Placebo (similar smelling placebo, 2 ml diluted in 50 ml water, administered 15 minutes before EEG recording)
Number of subjects: 42
Study 18559301 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian/hops fluid extract
Number of subjects: 42
Study 17402322 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 157
Study 17402322 — intervention group
Group type: COMPARATOR
Intervention: Minilaparotomy cholecystectomy (MC)
Number of subjects: 157
Study 15321024 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%
Number of subjects: 19
Study 15321024 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 19
Study 15321024 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine 0.2%
Number of subjects: 19
Study 15321024 — intervention group
Group type: COMPARATOR
Intervention: Betaxolol 0.25%
Number of subjects: 19
Study 11217678 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg DKPT t.i.d. (n = 97)
Number of subjects: 192
Study 11217678 — intervention group
Group type: COMPARATOR
Intervention: 50 mg TRAM t.i.d. (n = 95)
Number of subjects: 192
Study 9291421 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY x 7195 (500 mg, single oral dose)
Number of subjects: 10
Study 9291421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8326271 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (AIDS education programme)
Number of subjects: 337
Study 8326271 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 337
Study 8326271 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 337
Study 2873760 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium, 0.5 mg/kg
Number of subjects: 60
Study 2873760 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium, 1.0 mg/kg
Number of subjects: 60
Study 2873760 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium, 0.1 mg/kg
Number of subjects: 60
Study 2873760 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium, 0.2 mg/kg
Number of subjects: 60
Study 2873760 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium, 1.0 mg/kg (rapid sequence induction)
Number of subjects: 60
Study 2873760 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium, 0.2 mg/kg (rapid sequence induction)
Number of subjects: 60
Study 29470308 — intervention group
Group type: EXPERIMENTAL
Intervention: IAI 2 mg every 4 weeks (2q4)
Number of subjects: 403
Study 29470308 — intervention group
Group type: EXPERIMENTAL
Intervention: IAI 2 mg every 4 weeks until Week 16 then 8-week dosing (2q8)
Number of subjects: 403
Study 29470308 — intervention group
Group type: COMPARATOR
Intervention: Laser
Number of subjects: 403
Study 29470308 — intervention group
Group type: EXPERIMENTAL
Intervention: IAI 2q8 in VIVID-Japan
Number of subjects: 403
Study 26927286 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 4g daily for 7 days
Number of subjects: 0
Study 26927286 — intervention group
Group type: COMPARATOR
Intervention: Placebo pills
Number of subjects: 0
Study 25464065 — intervention group
Group type: EXPERIMENTAL
Intervention: Large portion labeled as 'Contains 4 servings'
Number of subjects: 100
Study 25464065 — intervention group
Group type: COMPARATOR
Intervention: Large portion labeled as 'Contains 2 servings'
Number of subjects: 100
Study 25464065 — intervention group
Group type: COMPARATOR
Intervention: Large portion unlabeled
Number of subjects: 100
Study 25464065 — intervention group
Group type: COMPARATOR
Intervention: Small portion
Number of subjects: 100
Study 23233708 — intervention group
Group type: EXPERIMENTAL
Intervention: Video decision support tool (3-minute video depicting CPR)
Number of subjects: 150
Study 23233708 — intervention group
Group type: COMPARATOR
Intervention: Verbal narrative describing CPR
Number of subjects: 150
Study 23233708 — intervention group
Group type: EXPERIMENTAL
Intervention: Video decision support tool (3-minute video)
Number of subjects: 150
Study 21696108 — intervention group
Group type: EXPERIMENTAL
Intervention: Pendulum appliance
Number of subjects: 30
Study 21696108 — intervention group
Group type: COMPARATOR
Intervention: Cervical headgear (CHG)
Number of subjects: 30
Study 19111270 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagram method (patients viewed a set of diagrams illustrating the 12 key points before signing the informed-consent form)
Number of subjects: 99
Study 19111270 — intervention group
Group type: EXPERIMENTAL
Intervention: Teach-the-teacher method (patients had to repeat the 12 key points to the physicians before informed consent was complete)
Number of subjects: 99
Study 19111270 — intervention group
Group type: COMPARATOR
Intervention: Control group (informed consent obtained in the customary manner with 12 key points discussed conversationally)
Number of subjects: 99
Study 19111270 — intervention group
Group type: EXPERIMENTAL
Intervention: Teach-the-teacher group
Number of subjects: 99
Study 17042248 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated tube food (200 mg)
Number of subjects: 12
Study 17042248 — intervention group
Group type: COMPARATOR
Intervention: Placebo tube food
Number of subjects: 12
Study 12953899 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal MU subtraction
Number of subjects: 11
Study 12953899 — intervention group
Group type: COMPARATOR
Intervention: Portal filming without MU subtraction
Number of subjects: 11
Study 10775736 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxybutynin
Number of subjects: 226
Study 10775736 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release oxybutynin
Number of subjects: 226
Study 9068331 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (n = 26, median dose 157 mg over 70 s)
Number of subjects: 51
Study 9068331 — intervention group
Group type: COMPARATOR
Intervention: Etomidate (n = 25, median dose 16.2 mg in 57 s)
Number of subjects: 51
Study 8311162 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinon
Number of subjects: 58
Study 8311162 — intervention group
Group type: EXPERIMENTAL
Intervention: Danason
Number of subjects: 58
Study 8311162 — intervention group
Group type: COMPARATOR
Intervention: Menstrual fluid of patients with profuse uterine bleedings
Number of subjects: 58
Study 3518527 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified and standardized Cladosporium herbarum allergen preparation (active treatment)
Number of subjects: 0
Study 3518527 — intervention group
Group type: COMPARATOR
Intervention: Histamine placebo (control)
Number of subjects: 0
Study 31331339 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine follow-up (RFU) with one extra medical visit and additional visits to the Cardiology and Respiratory Medicine Clinics 1 and 3 months postoperatively
Number of subjects: 198
Study 31331339 — intervention group
Group type: COMPARATOR
Intervention: Routine follow-up (RFU)
Number of subjects: 198
Study 28836375 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) session before periodontal treatment
Number of subjects: 26
Study 28836375 — intervention group
Group type: COMPARATOR
Intervention: Conventional educational intervention and non-surgical periodontal therapy
Number of subjects: 26
Study 27716125 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysphagia-optimised intensity-modulated radiotherapy (Do-IMRT)
Number of subjects: 0
Study 27716125 — intervention group
Group type: COMPARATOR
Intervention: Standard intensity-modulated radiotherapy (S-IMRT)
Number of subjects: 0
Study 24681572 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich concentrated beetroot juice (NIT; nitrate dosage, approximately 9.7 mmol·d)
Number of subjects: 19
Study 24681572 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich concentrated beetroot juice (NIT)
Number of subjects: 19
Study 24681572 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 19
Study 22198714 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 8844
Study 22198714 — intervention group
Group type: COMPARATOR
Intervention: CT-colonography
Number of subjects: 8844
Study 20545407 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Family Therapy (FFT)
Number of subjects: 0
Study 20545407 — intervention group
Group type: COMPARATOR
Intervention: Probation services (Control)
Number of subjects: 0
Study 17549677 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin formulation product after oral administration
Number of subjects: 0
Study 16208152 — intervention group
Group type: EXPERIMENTAL
Intervention: HCTZ 25 mg added to olmesartan 20 mg
Number of subjects: 0
Study 16208152 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan/HCTZ 20/12.5 mg
Number of subjects: 0
Study 16208152 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan/HCTZ 20/25 mg
Number of subjects: 0
Study 16208152 — intervention group
Group type: EXPERIMENTAL
Intervention: HCTZ 12.5 mg
Number of subjects: 0
Study 16208152 — intervention group
Group type: EXPERIMENTAL
Intervention: HCTZ 25 mg
Number of subjects: 0
Study 16208152 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to olmesartan
Number of subjects: 0
Study 11149993 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA
Number of subjects: 18
Study 11149993 — intervention group
Group type: COMPARATOR
Intervention: BAC (positive control)
Number of subjects: 18
Study 11149993 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 18
Study 9893775 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release oral salbutamol (CR) 8 mg b.d. for > or = 3 days
Number of subjects: 0
Study 9893775 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose inhaled salmeterol xinafoate (SX) 100 micrograms b.d. for > or = 3 days
Number of subjects: 0
Study 7924887 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,5-anhydroglucitol (AG) quantitation method
Number of subjects: 15
Study 3410812 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech Alone
Number of subjects: 60
Study 3410812 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous Presentation of Sign and Speech
Number of subjects: 60
Study 3410812 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating Presentation of Sign and Speech
Number of subjects: 60
Study 3410812 — intervention group
Group type: COMPARATOR
Intervention: Sign Alone
Number of subjects: 60
Study 30547847 — intervention group
Group type: EXPERIMENTAL
Intervention: SUMMIT intervention
Number of subjects: 100
Study 30547847 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 100
Study 26713333 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg per day)
Number of subjects: 100
Study 26713333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 25205864 — intervention group
Group type: COMPARATOR
Intervention: Genetic variants rs1061170 (CFH) and rs10490924 (ARMS2) in European Americans
Number of subjects: 0
Study 25205864 — intervention group
Group type: COMPARATOR
Intervention: Genetic variant rs10490924 (ARMS2) in Mexican Americans
Number of subjects: 0
Study 25205864 — intervention group
Group type: COMPARATOR
Intervention: Lipid-associated SNPs (LPL rs328, TRIB1 rs6987702, CETP rs1800775, KCTD10/MVK rs2338104) in African Americans and Mexican Americans
Number of subjects: 0
Study 22909321 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 200
Study 22909321 — intervention group
Group type: COMPARATOR
Intervention: Physical Activity
Number of subjects: 200
Study 20628384 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct referral for colposcopy
Number of subjects: 0
Study 20628384 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated testing among HPV-positive/cytology-negative women
Number of subjects: 0
Study 20628384 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 17509336 — intervention group
Group type: EXPERIMENTAL
Intervention: Double‐J stent
Number of subjects: 201
Study 17509336 — intervention group
Group type: COMPARATOR
Intervention: No-stent
Number of subjects: 201
Study 15629562 — intervention group
Group type: EXPERIMENTAL
Intervention: CPREzy
Number of subjects: 20
Study 15629562 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 20
Study 12564619 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c analysis using Tosoh method
Number of subjects: 430
Study 10817105 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR (100-300 mg/day)
Number of subjects: 100
Study 10817105 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (10-40 mg/day)
Number of subjects: 100
Study 8788597 — intervention group
Group type: EXPERIMENTAL
Intervention: FK453 (50 mg)
Number of subjects: 13
Study 8788597 — intervention group
Group type: EXPERIMENTAL
Intervention: FK453 (200 mg)
Number of subjects: 13
Study 8788597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 1345050 — intervention group
Group type: EXPERIMENTAL
Intervention: Active antihypertensive therapy
Number of subjects: 1627
Study 1345050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1627
Study 6436935 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg sustained release theophylline
Number of subjects: 16
Study 6436935 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg sustained release theophylline
Number of subjects: 16
Study 6436935 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg and 450 mg sustained release theophylline
Number of subjects: 16
Study 30696471 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated VR cognitive treatment
Number of subjects: 0
Study 30696471 — intervention group
Group type: COMPARATOR
Intervention: VR mental relaxation (control condition)
Number of subjects: 0
Study 28966154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical bone trajectory-pedicle screw (CS)
Number of subjects: 79
Study 28966154 — intervention group
Group type: COMPARATOR
Intervention: Conventional pedicle screw (PS)
Number of subjects: 79
Study 26850472 — intervention group
Group type: EXPERIMENTAL
Intervention: Road Traffic Injuries (RTIs)
Number of subjects: 5148
Study 26850472 — intervention group
Group type: EXPERIMENTAL
Intervention: Household impact of RTIs
Number of subjects: 5148
Study 24215774 — intervention group
Group type: EXPERIMENTAL
Intervention: Social and mobile weight loss intervention
Number of subjects: 404
Study 24215774 — intervention group
Group type: COMPARATOR
Intervention: Informational web‐based weight loss program
Number of subjects: 404
Study 22270284 — intervention group
Group type: COMPARATOR
Intervention: Transobturator tape (TOT)
Number of subjects: 164
Study 22270284 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 164
Study 22270284 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-of-life outcomes (both groups)
Number of subjects: 164
Study 20183394 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy processes measured by the Working Alliance Inventory‐Short Form
Number of subjects: 145
Study 20183394 — intervention group
Group type: EXPERIMENTAL
Intervention: Merged three‐factor model consisting of member‐leader alliance, positive bonding relationship, and negative relationship
Number of subjects: 145
Study 20183394 — intervention group
Group type: EXPERIMENTAL
Intervention: Member-leader bonding
Number of subjects: 145
Study 20183394 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohesion and alliance
Number of subjects: 145
Study 17973865 — intervention group
Group type: EXPERIMENTAL
Intervention: N(G)-monomethyl-L-arginine (L-NMMA) at 1 mmol/L
Number of subjects: 30
Study 17973865 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric dimethylarginine (ADMA) at 1 mmol/L
Number of subjects: 30
Study 17973865 — intervention group
Group type: EXPERIMENTAL
Intervention: L-leucine at 1 mmol/L
Number of subjects: 30
Study 17973865 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen-induced platelet aggregation
Number of subjects: 30
Study 17973865 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal NOS activity and intraplatelet cGMP levels
Number of subjects: 30
Study 17973865 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma concentrations of fibrinogen, C-reactive protein, and cytokines
Number of subjects: 30
Study 15848326 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal (600mg/d)
Number of subjects: 193
Study 15848326 — intervention group
Group type: COMPARATOR
Intervention: Acenocoumarol (target INR 2.0‐3.0)
Number of subjects: 193
Study 15848326 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal
Number of subjects: 193
Study 15848326 — intervention group
Group type: COMPARATOR
Intervention: Acenocoumarol
Number of subjects: 193
Study 11502777 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone therapy (32 patients treated)
Number of subjects: 37
Study 11502777 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 37
Study 11502777 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone therapy (in responders)
Number of subjects: 37
Study 11502777 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (in responders)
Number of subjects: 37
Study 9266258 — intervention group
Group type: COMPARATOR
Intervention: Whole blood cultures (WBC) stimulated with lipopolysaccharide (LPS)
Number of subjects: 0
Study 9266258 — intervention group
Group type: COMPARATOR
Intervention: Whole blood cultures (WBC) stimulated with whole killed Salmonella typhimurium
Number of subjects: 0
Study 9266258 — intervention group
Group type: COMPARATOR
Intervention: Whole blood cultures (WBC) stimulated with Staphylococcus aureus
Number of subjects: 0
Study 9266258 — intervention group
Group type: COMPARATOR
Intervention: Whole blood cultures (WBC) stimulated with concanavalin A (ConA)
Number of subjects: 0
Study 9266258 — intervention group
Group type: COMPARATOR
Intervention: Whole blood cultures (WBC) stimulated with LPS
Number of subjects: 0
Study 9266258 — intervention group
Group type: COMPARATOR
Intervention: Whole blood cultures (WBC) stimulated with other bacterial components
Number of subjects: 0
Study 9266258 — intervention group
Group type: COMPARATOR
Intervention: Whole blood cultures (WBC)
Number of subjects: 0
Study 7508066 — intervention group
Group type: EXPERIMENTAL
Intervention: diet and fluid plus indapamide 2.5 mg/day (group B)
Number of subjects: 75
Study 7508066 — intervention group
Group type: EXPERIMENTAL
Intervention: diet and fluid plus indapamide 2.5 mg/day plus allopurinol 300 mg/day (group C)
Number of subjects: 75
Study 7508066 — intervention group
Group type: COMPARATOR
Intervention: diet and fluid (group A)
Number of subjects: 75
Study 3106449 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 micrograms)
Number of subjects: 10
Study 3106449 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Cromoglycate (SCG) (10 mg)
Number of subjects: 10
Study 3106449 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (200 micrograms)
Number of subjects: 10
Study 3106449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2685081 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (200 mg every 8 h for 2 weeks, then 200 mg/day)
Number of subjects: 34
Study 2685081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 31976548 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetramethylpyrazine (TMP) 100 mg·kg‐1 ·day‐1 in animal models (Sprague-Dawley rats)
Number of subjects: 0